Navion Neurosciences

Navion Neurosciences is a preclinical-stage biotechnology company developing next-generation, precision sodium channel therapeutics for neurological diseases. Spun out of the University of Virginia and formerly known as GenEp, the company utilizes its AI-enabled NaViGATion™ discovery platform to integrate chemistry, structural biology, human disease biology, and deep ion-channel expertise. Navion's pipeline focuses on addressing pathological neuronal hyperexcitability, a key driver of uncontrolled seizures and chronic pain, with lead programs in genetic epilepsy and chronic neuropathic pain. By achieving precise modulation of disease-relevant sodium-channel activity, the company aims to dramatically improve the therapeutic window compared to traditional broad-spectrum approaches.